Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150473 | 0.87 | CASP3 (0.45) | PKMKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL7147947 | 0.86 | MAPT (0.42) | ADRB3ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7150268 | 0.82 | POLB (0.41) | HTR6POLBADRB2ADRB1ADRB3 | |
| SCHEMBL3809843 | 0.81 | POLB (0.40) | HTR6POLBADRB2ADRB1ADRB3 | |
| SCHEMBL7148734 | 0.73 | POLB (0.43) | HTR6POLBPKMKMT2AALDH1A1 | |
| SCHEMBL3841758 | 0.71 | POLB (0.39) | HTR6POLBADRB2ADRB1ADRB3 | |
| SCHEMBL27564740 | 0.70 | POLB (0.52) | HTR6POLBADRB2ADRB1ADRB3 | |
| SCHEMBL7143100 | 0.69 | KMT2A (0.51) | PKMKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL3811615 | 0.69 | ALDH1A1 (0.53) | PKMKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL7194810 | 0.68 | POLB (0.46) | HTR6POLBADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1347783-A1 | CONJUGATES OF INTEGRIN RECEPTOR ANTAGONISTS AND A CYTOSTATIC AGENT HAVING SPECIFICALLY CLEAVABLE LINKING UNITS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-20020183256-A1 | Cytostatic-integrin conjugates having specifically cleavable linking units | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-05 | — | — | US | disclosed |
| EP-1238678-A1 | Enzyme-activated cytostatic conjugates with integrin ligands | Bayer Aktiengesellschaft (DE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002051444-A1 | CONJUGATES OF INTEGRIN RECEPTOR ANTAGONISTS AND A CYTOSTATIC AGENT HAVING SPECIFICALLY CLEAVABLE LINKING UNITS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1219305-A1 | Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units | Bayer Aktiengesellschaft (DE) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183256-A1 | Cytostatic-integrin conjugates having specifically cleavable linking units | ITGAV, ITGB3, ITGAL | HTR6 3289/4885POLB 2115/4885ADRB2 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.